Patient Capital Management's "Patient Opportunity Equity Strategy" had a strong fourth quarter in 2025, with a net return of 5.99%, surpassing the S&P 500 Index's 2.65% return. This outperformance was attributed to effective allocation, selection, and interactive strategies. The year 2025, characterized by advancements in artificial intelligence that benefited hardware, energy, and component suppliers, concluded with the market achieving a 17.9% return, marking one of the best three-year periods in market history. Despite the dominance of seven stocks contributing over half of the S&P 500's returns, posing challenges for active managers, the strategy achieved a 26.1% return, outperforming the S&P 500 for the third consecutive year.
A key contributor to the Patient Opportunity Equity Strategy's success in the fourth quarter of 2025 was Precigen, Inc. (NASDAQ: PGEN). This discovery and clinical-stage biopharmaceutical company specializes in developing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases. The company's stock closed at $3.55 per share on March 4, 2026, showcasing an impressive 89.84% gain over the previous 52 weeks, despite a -16.27% return in the last month. With a market capitalization of $1.256 billion, Precigen's progress is largely driven by its leadership.
The early approval of Papziemos for recurrent respiratory papillomatosis (RRP) in early August was a major catalyst for Precigen. This therapy represents a significant breakthrough as the first-in-class "off-the-shelf" immunotherapy for RRP patients, who previously had no other treatment options. As Precigen moves rapidly to launch this drug, it is moving closer to becoming self-sufficient, which will enable the company to further develop its other pipeline assets. Under the leadership of Dr. Helen Sabzevari, who brings extensive experience in immunotherapy, having founded and served as Chief Scientific Officer of Compass Therapeutics, Precigen has made remarkable clinical advancements. It is anticipated that a similar approach will be applied to the company's other pipeline assets currently in Phase 1/1b and Phase 2 development, suggesting substantial potential for growth with several blockbuster assets in its portfolio.
Precigen's achievements highlight the transformative power of biomedical innovation and strategic leadership in addressing critical medical needs. The development of groundbreaking therapies not only offers hope to patients but also creates significant opportunities for growth and investment. Investing in companies that push the boundaries of science and healthcare can lead to positive societal and economic outcomes.
